Cargando…

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells

Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDEC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diersch, Sandra, Wirth, Matthias, Schneeweis, Christian, Jörs, Simone, Geisler, Fabian, Siveke, Jens T., Rad, Roland, Schmid, Roland M., Saur, Dieter, Rustgi, Anil K., Reichert, Maximilian, Schneider, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877299/ https://www.ncbi.nlm.nih.gov/pubmed/26592448 http://dx.doi.org/10.1038/onc.2015.437

Ejemplares similares

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC
por: Lankes, Katharina, et al.
Publicado: (2020)

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
por: Schneeweis, Christian, et al.
Publicado: (2022)

Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008)

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer
por: Schneeweis, Christian, et al.
Publicado: (2022)

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells
por: Schüler, Susanne, et al.
Publicado: (2010)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Rationale for MYC imaging and targeting in pancreatic cancer
por: Schneider, Günter, et al.
Publicado: (2021)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
por: Wirth, Matthias, et al.
Publicado: (2014)

Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
por: Diersch, Sandra, et al.
Publicado: (2013)

The Pancreatic and Duodenal Homeobox Protein PDX-1 Regulates the Ductal Specific Keratin 19 through the Degradation of MEIS1 and DNA Binding
por: von Burstin, Johannes, et al.
Publicado: (2010)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)

Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions
por: Lubeseder-Martellato, Clara, et al.
Publicado: (2016)

Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Falcomatà, Chiara, et al.
Publicado: (2023)

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging
por: Kaissis, Georgios, et al.
Publicado: (2019)

Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma
por: Kaissis, Georgios A., et al.
Publicado: (2020)

Membranous CD24 drives the epithelial phenotype of pancreatic cancer
por: Lubeseder-Martellato, Clara, et al.
Publicado: (2016)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
por: Mueller, Sebastian, et al.
Publicado: (2018)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
por: Kaissis, Georgios, et al.
Publicado: (2019)

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
por: Biederstädt, Alexander, et al.
Publicado: (2020)

HDAC2 Facilitates Pancreatic Cancer Metastasis
por: Krauß, Lukas, et al.
Publicado: (2022)

KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE)
por: Veits, Lothar, et al.
Publicado: (2014)

[(18)F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
por: Harder, Felix N., et al.
Publicado: (2021)

Linkage of genetic drivers and strain-specific germline variants confound mouse cancer genome analyses
por: Mueller, Sebastian, et al.
Publicado: (2020)

Identification of Epidermal Pdx1 Expression Discloses Different Roles of Notch1 and Notch2 in Murine Kras(G12D)-Induced Skin Carcinogenesis In Vivo
por: Mazur, Pawel K., et al.
Publicado: (2010)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Genetic Screens Identify a Context-Specific PI3K/p27(Kip1) Node Driving Extrahepatic Biliary Cancer
por: Falcomatà, Chiara, et al.
Publicado: (2021)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Interstitial cells of Cajal link excitatory and nitrergic inhibitory neurotransmission with slow-wave activity in the intestine
por: Klein, Sabine, et al.
Publicado: (2013)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

The NF-κB Subunit RelA/p65 Is Dispensable for Successful Liver Regeneration after Partial Hepatectomy in Mice
por: Ringelhan, Marc, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rgbgjkg4atcv0s4c2dfu01qrp3